T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib).

Authors:
Geling Li
Geling Li
Walther Oncology Center
Julie Wolfson
Julie Wolfson
Childrens Hospital Los Angeles
United States

Blood Adv 2017 Dec 18;1(27):2724-2728. Epub 2017 Dec 18.

Institute for Cancer Outcomes and Survivorship, School of Medicine, University of Alabama at Birmingham, Birmingham, AL.

A 19-year-old ataxia-telangiectasia patient with T-cell prolymphocytic leukemia harbored 2 -activating hotspot mutations.The patient suffered toxicities with chemotherapy, but demonstrated a clinical response to novel use of a JAK3 inhibitor (tofacitinib).

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2017010470DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745136PMC
December 2017
4 Reads

Publication Analysis

Top Keywords

jak3 inhibitor
8
prolymphocytic leukemia
8
inhibitor tofacitinib
8
t-cell prolymphocytic
8
-activating hotspot
4
hotspot mutationsthe
4
harbored -activating
4
ataxia-telangiectasia patient
4
leukemia harbored
4
mutationsthe patient
4
suffered toxicities
4
clinical response
4
response novel
4
novel jak3
4
demonstrated clinical
4
chemotherapy demonstrated
4
19-year-old ataxia-telangiectasia
4
toxicities chemotherapy
4
patient suffered
4
patient t-cell
4

Similar Publications

Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.

Genes Chromosomes Cancer 2014 Apr 21;53(4):309-16. Epub 2014 Jan 21.

Institute for Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Department of Pediatrics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

T-cell prolymphocytic leukemia (T-PLL) is an aggressive post-thymic T-cell malignancy characterized by the recurrent inv(14)(q11q32)/t(14;14)(q11;q32) or t(X;14)(q28;q11) leading to activation of either the TCL1 or MTCP1 gene, respectively. However, these primary genetic events are insufficient to drive leukemogenesis. Recently, activating mutations in JAK3 have been identified in other T-cell malignancies. Read More

View Article
April 2014

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.

Blood 2014 Aug 13;124(9):1460-72. Epub 2014 May 13.

Department of Pathology, University of Michigan Medical School, Ann Arbor, MI;

The comprehensive genetic alterations underlying the pathogenesis of T-cell prolymphocytic leukemia (T-PLL) are unknown. To address this, we performed whole-genome sequencing (WGS), whole-exome sequencing (WES), high-resolution copy-number analysis, and Sanger resequencing of a large cohort of T-PLL. WGS and WES identified novel mutations in recurrently altered genes not previously implicated in T-PLL including EZH2, FBXW10, and CHEK2. Read More

View Article
August 2014

Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.

Am J Pathol 2017 May 9;187(5):980-986. Epub 2017 Mar 9.

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

Inhibition of the Janus kinase (JAK)-STAT pathway has been implicated as a treatment option for extranodal natural killer/T-cell lymphoma, nasal type (NTCL). However, JAK-STAT pathway alterations in NTCL are variable, and the efficacy of JAK-STAT pathway inhibition has been poorly evaluated. JAK3 mutation and STAT3 genetic alterations were investigated by direct sequencing and immunohistochemistry in 84 patients with newly diagnosed NTCL. Read More

View Article
May 2017

A gene on chromosome Xq28 associated with T-cell prolymphocytic leukemia in two patients with ataxia telangiectasia.

Leukemia 1994 Apr;8(4):564-73

Department of Cancer Studies, University of Birmingham, UK.

A t(X;14)(q28;q11) translocation was present for many years in T cells in two patients with ataxia telangiectasia (A-T), who subsequently developed T-prolymphocytic leukemia. We describe here the relationship between the translocation breakpoints in these patients with respect to two recently described genes, c6.1A and c6. Read More

View Article
April 1994